I have a few comments and questions as follows. Most of these issues could be elaborated in the Discussion part, as "strengths and limitations of the design", others in other appropriate sections.
1) It would be helpful for the international readers if you elaborated shortly on how primary care is organized in Australia. This might answer possible questions about whether, for example, economical incentives could affect the clinics willingness to participate in the trial. 2) Page 11, line 3: A clarifying of why you chose cluster randomization is needed; I would say the main reason for this is that this design has the ability to control for "contamination" across individuals, that is, researchers must account for the fact that two patients sampled from a single clinic are more likely to be similar (in terms of outcomes) than two patients sampled from different clinics. 3) Page 10, line 22, and page 12: I would like to see a short elaboration about not choosing any symptom parameters for the diagnostics in your inclusion criteria, since this is at the moment much discussed in the GOLD 2017 guidelines. Using only spirometry is of course practical in a research setting, but it involves a risk of including non-COPD-patients (like under-controlled asthma patients) or end up with very heterogeneous group of COPD patients (all four sorts of COPD A-D). You will assess the symptoms and exacerbations after the inclusion (which gives you the possibility to grade all stages of COPD A-D), and this in itself will be a good information -but with your planned total group size you might find each subgroup quite small, and therefore have difficulties with making conclusions of the results. 4) Page 10, line 19: Do you mean "any visits" or "visits due to airway symptoms (COPD)"? 5) Page 10, line 21: Why include non-smokers, if the main intervention has to do with smoking cessation support, according to page 9, lines 24-26? 6) Page 11, line 16: An elaboration on choosing the FEV1/FEV6 limit 0.75 is needed, as there are other studies found in the literature suggesting lower limits (0.73, or 0.72). The higher limit (0.75) will give you larger margins of not missing anyone with a possible COPD, especially because your targets are most likely younger patients (early detection of COPD) -but it might lead to a (possibly unnecessarily) high number of patients you will have to send to spirometry testing, which can be important in planning for time needed, resources and staffing. 7) About the power calculation: Due to a quite extensive data collection per patient, there just might be a risk of patient drop-outs during the 12-mnth period, simply due to the fact the patients will not want to go through the trouble of the interview procedure once (and twice) more. I do think that your 22% drop out calculation (140 patients required in the base line, 108 patients needed at the endline, per arm), especially for the "usual care" group, might be a bit optimistic. 8) Page 14, line 20: You plan to collect the data in different ways. This might influence the quality of the data by bias due to different lengths of time used to replying to the questions, possible help and assistance from other people (i.e. family members), being nervous or unsecure at an interview situation etc.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1
Major: 1. Several of the most recent intervention studies on COPD have shown that increasing the patients ` knowledge of COPD and how to handle the exacerbations is a crucial factor explaining increased HRQoL. However, the intervention in the present protocol does not contain any education program for the participants concerning the disease COPD, how the medication works, how to prevent exacerbations etc. We acknowledge the positive effects of patient education, especially handling of exacerbations, on HRQoL in patients with moderate to severe COPD. Although we have not given details of the education program within the manuscript, each of the intervention components involve providing education to participants and references have been made to our previous work in this area. As part of the home medicines review (HMR) service, the consultant pharmacist not only reviews and assesses respiratory and non-respiratory medication use (including inhaler technique), but also provides education, and rectifies any issues with medication adherence, and/or medication knowledge (Page 15, lines 8-10). As part of the home-based pulmonary rehabilitation program, participants receive weekly phone calls to discuss exercise goals, and discussion of disease-specific self-management training. Trained physiotherapists delivering the home-based pulmonary rehabilitation component refer to this guide during their weekly phone calls to patients for discussion.
2. The primary aim is to determine the efficacy, for patients with COPD, of the RADICALS compared to usual care on HRQoL using SGRQ. I do not find a justification in the text why this intervention should lead to a significant change in the SGRQ score, either the total score or the domain score. It has been shown that the number of severe exacerbations is associated to HRQoL measured by SGRQ, but it is debated whether SGRQ is a good tool to measure effects of intervention programs among patients with COPD. Also, it is not likely that HRQoL is reduced among cigarette smokers with mild COPD. The authors ought to reconsider what is the primary aim of the study and what is the best tool to measure an eventual change. Would it be more relevant to find a good measure of changes in "self-efficacy"?
The main aims of our study were to improve COPD diagnosis amongst long-term smokers and to test the efficacy of the RADICALS intervention (which involves smoking cessation support, if relevant; home-based pulmonary rehabilitation; and pharmacist-led medication review) at improving HRQoL of both new and existing cases of COPD. The SGRQ is used extensively in studies of pulmonary rehabilitation (a key component of RADICALS) across the spectrum of COPD severity. It is a highly responsive outcome for pulmonary rehabilitation studies in patients with moderate to severe COPD severity. Studies have also shown positive effects of pulmonary rehabilitation on SGRQ in patients with mild COPD for up to six months following the intervention. We refer to the Australian and New Zealand Pulmonary Rehabilitation Guidelines, which includes a meta-analysis for effects of PR on SGRQ in mild disease. Alison JA, McKeough ZJ, Johnston K, et al. Australian and New Zealand Pulmonary Rehabilitation Guidelines. Respirology 2017;22(4):800-19. The use of the SGRQ enables us to capture potential HRQoL effects of the RADICALS intervention and patients" health status across all COPD severity groups.
3. What is the rationale to include both the CAT score and mMRC Dyspnea Scale? CAT scores and mMRC scores have been included as secondary outcomes to examine the effects of the intervention on participants" daily activities and symptoms (dyspnoea). These are common outcome measures used in studies of COPD patients (of varying severity).
Minor: 1. Inclusion and exclusion criteria; Are at least two visits to "the practice" a premise both for participants without and participants with a COPD diagnosis? Yes, at least two visits in the previous 12 months to the general practice is an inclusion criterion for both of the above groups. We use this as a measure of patient engagement with the practice and will potentially avoid the recruitment of patients who may have just visited the practice once-off. The protocol has been updated to explain this (Page 11, .
Reviewer: 2
Comments to the authors:
1) It would be helpful for the international readers if you elaborated shortly on how primary care is organized in Australia. This might answer possible questions about whether, for example, economical incentives could affect the clinics willingness to participate in the trial. Please see additional information about primary care in Australia now added to the manuscript (Page 8, lines 7-25).
2) Page 11, line 3: A clarifying of why you chose cluster randomization is needed; I would say the main reason for this is that this design has the ability to control for "contamination" across individuals, that is, researchers must account for the fact that two patients sampled from a single clinic are more likely to be similar (in terms of outcomes) than two patients sampled from different clinics. We agree. The rationale behind using cluster randomisation is already described on Page 11, lines 1-2: "Cluster randomisation of clinics minimises the risk of contamination associated with the same practice staff managing patients from both control and intervention groups." It is also listed as one of the strengths of the study on page 25, lines 2-3.
3) Page 10, line 22, and page 12: I would like to see a short elaboration about not choosing any symptom parameters for the diagnostics in your inclusion criteria, since this is at the moment much discussed in the GOLD 2017 guidelines. Using only spirometry is of course practical in a research setting, but it involves a risk of including non-COPD-patients (like under-controlled asthma patients) or end up with very heterogeneous group of COPD patients (all four sorts of COPD A-D). You will assess the symptoms and exacerbations after the inclusion (which gives you the possibility to grade all stages of COPD A-D), and this in itself will be a good information -but with your planned total group size you might find each subgroup quite small, and therefore have difficulties with making conclusions of the results. We acknowledge the growing use of symptom parameters and A-D grading for COPD diagnosis as discussed in the GOLD 2017 guidelines. Please note that our study was designed based on the COPD-X guidelines, developed by the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia, which do not use the A-D classification. We will be doing sub-group analysis based on severity, but not symptoms. However, we acknowledge that this may limit the applications of the findings to other populations where the A-D classification may be used. See this acknowledgement in the Discussion on Page 25 lines 6-12.
4) Page 10, line 19: Do you mean "any visits" or "visits due to airway symptoms (COPD)"? Two or more visits to the practice -refers to any visits. It is simply a measure of patient engagement. See our response to the minor comment from Reviewer #1. 5) Page 10, line 21: Why include non-smokers, if the main intervention has to do with smoking cessation support, according to page 9, lines 24-26? Those without a history of smoking may have been exposed to second-hand smoke at home or other exposures at the workplace and have developed COPD. They may also benefit from the other components of the RADICALS intervention (i.e. home-based pulmonary rehabilitation and home medicines review). Those with no history of smoking are eligible only if they are managed as having COPD as per practice records, which will be confirmed using spirometry as part of the trial. Underdiagnosis of COPD is common in primary care; people who have already quit smoking (ex-smokers) may have developed COPD from their previous smoking. The smoking cessation support component of the RADICALS intervention will be offered only to those relevant (please refer to Page 13 lines 21-22, and updated Figure 1 7) About the power calculation: Due to a quite extensive data collection per patient, there just might be a risk of patient drop-outs during the 12-mnth period, simply due to the fact the patients will not want to go through the trouble of the interview procedure once (and twice) more. I do think that your 22% drop out calculation (140 patients required in the base line, 108 patients needed at the endline, per arm), especially for the "usual care" group, might be a bit optimistic. Although follow-ups are not fully complete, our attrition rate for COPD patients is currently around 13%. As outlined under statistical analysis, our primary analysis will be an intention-to-treat (ITT) analysis which will include all patients randomised, regardless of drop-outs or loss to follow-ups. We will use appropriate statistical methods for handling missing data, including multiple imputation and sensitivity analyses. Nonetheless, strategies for minimising attrition will be employed, including offering travel reimbursement for follow-up spirometry and exhaled carbon monoxide testing, shorter questionnaires and mail correspondence where face-to-face or telephone interviews are not possible.
8) Page 14, line 20: You plan to collect the data in different ways. This might influence the quality of the data by bias due to different lengths of time used to replying to the questions, possible help and assistance from other people (i.e. family members), being nervous or unsecure at an interview situation etc. All baseline data will be collected during a face-to-face interview. Insisting on a face-to-face interview for all follow-ups could result in withdrawal/drop-out of some participants. See our response to Reviewer #2 comment #8, outlining strategies which will be employed to avoid missing data during follow-up. We will perform sensitivity analyses to identify any treatment effects based on the method of follow-up. 
GENERAL COMMENTS
This paper presents the protocol for a cluster randomized controlled trial. The objectives are early detection and management of chronic obstructive pulmonary disease (COPD) in Australian primary care. The intervention methods are thoroughly described, and the rationale for why the numerous registrations and questionnaires are chosen is nicely accounted for. This is an ambitious and interesting study that has the potential to illuminate the effect of the ERS/ATS guidelines when implemented in primary care. 
REVIEWER

VERSION 2 -AUTHOR RESPONSE
Minor comments addressed:
#2: Page 11, line 3: A clarifying of why you chose cluster randomization is needed; I would say the main reason for this is that this design has the ability to control for "contamination" across individuals, that is, researchers must account for the fact that two patients sampled from a single clinic are more likely to be similar (in terms of outcomes) than two patients sampled from different clinics. First response: We agree. The rationale behind using cluster randomisation is already described on Page 11, lines 1-2: "Cluster randomisation of clinics minimises the risk of contamination associated with the same practice staff managing patients from both control and intervention groups." It is also listed as one of the strengths of the study on page 25, lines 2-3. 
